Kobe University · Graduate School of Health Sciences · 教授

Research keywordsstem cell transplantation・vaccine immunogenicity・graft toxicity・lymphocyte recovery・B cell repertoire・veno occlusive disease

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• 日常的に計算可能な臨床的指標と、類洞閉塞症候群(SOS/VOD)の病勢進行との関連2024 · (一社)日本血液学会, 2024年10月, 日本血液学会学術集会, 86回, O2 - 3, 英語
• Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease.2023 · Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis of SOS/VOD is associated with improved clinical outcomes. In 2023, the refined European Society for Blood and Marrow Transplantation diagnostic and severity criteria (refined EBMT criteria 2023) have been advocated. The revision has introduced new diagnostic categories, namely; probable, clinical, and proven SOS/VOD. In addition, the Sequential Organ Failure Assessment (SOFA) score has been newly incorporated into the SOS/VOD severity grading. We performed a retrospective analysis to evaluate the utility of these criteria. We analyzed 161 cases who underwent allogeneic HSCT. We identified 53 probable, 23 clinical, and 4 proven SOS/VOD cases. Probable SOS/VOD was diagnosed a median of 5.0 days earlier (interquartile range: 2-13 days, P
• Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines.2023 · Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen-specific antibody sequence (QASAS) method to assess the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the coronavirus antibody database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines. We analyzed repeated blood samples of healthy volunteers before and after monovalent XBB.1.5 vaccination (BNT162b2 XBB.1.5 or mRNA-1273.815) for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.
• 血小板輸血不応の項を含む新診断基準による、類洞閉塞症候群(SOS)の早期診断2023 · (一社)日本血液学会, 2023年10月, 日本血液学会学術集会, 85回, 683 - 683, 英語

• 肥満・代謝異常の制御の標的としての基本的転写共役複合体メディエーター 伊藤 光宏 日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 2024年04月01日 - 2028年03月31日2024 · KUID parsed section
• 基本的転写共役因子複合体メディエーターからみた白血病ニッチの特性の解析 伊藤 光宏 学術研究助成基金助成金／基盤研究(C), 2017年04月 - 2020年03月, 研究代表者 競争的資金2017 · KUID parsed section
• 基本的転写共役因子MED1が担う乳癌の発症と特性 長谷川 菜摘, 伊藤 光宏 日本学術振興会, 科学研究費助成事業, 若手研究(B), 神戸大学, 2015年04月01日 - 2018年03月31日 私はこれまでに、基本的転写共役複合体メディエーターのサブユニット、MED1とMED24が協調し、エストロゲン受容体を介する正常マウスの乳腺の思春期発育やヒト乳癌細胞の増殖を担うことを報告した。本研究はこの成果を基盤に、MED1が乳癌の発症と特性、予後、治療反応性・抵抗性などにどのように寄与するかを個体レベル・分子レベルで明らかにするため、種々のMED1およびMED1結合蛋白の欠損マウスを用意した。既存のマウスと新規作成が完了したマウスについて順次、乳癌発症が抑制されうるか検討した。2015 · KUID parsed section
• メディエーター転写共役複合体が司る造血ニッチ維持機構と病態の解析 伊藤 光宏 学術研究助成基金助成金／基盤研究(C), 2014年04月 - 2017年03月, 研究代表者 競争的資金2014 · KUID parsed section

• Official profile